Genomics of lung cancer may change diagnosis, prognosis and therapy

Pathology and Oncology Research

Volumn 11, Issue 1, 2005, Pages 5-10

  Kopper, László ^a   Tímár, József ^b  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

Author keywords

Genomics; Lung cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; VASCULOTROPIN A; VASCULOTROPIN C;

CANCER GROWTH; CANCER SUSCEPTIBILITY; COMPARATIVE GENOMIC HYBRIDIZATION; EPIGENETICS; GENE EXPRESSION PROFILING; GENETIC MARKER; GENETIC SUSCEPTIBILITY; HETEROZYGOSITY LOSS; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; PROGNOSIS; SHORT SURVEY; TREATMENT PLANNING;

EID: 18444363612     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03032399     Document Type: Short Survey

References (52)

1. Schwartz AC: Genetic predisposition to lung cancer. Chest 125: 86S-89S, 2004
2. Olak J, Colson Y: Gender differences in lung cancer: Have we really come a long way, baby? J Thorac Cardiovasc Surg 128: 346-351, 2004
3. Minna JD, Roth JA, Gazdar AF: Focus on lung cancer. Cancer Cell 1: 49-52, 2002
4. Balsara BR, Testa JR: Chromosomal imbalances in human lung cancer. Oncogene 21: 6877-6883, 2002
5. Yokota J, Kohno T: Molecular footprints of human lung cancer progression. Cancer Sci 95: 197-204, 2004
6. Kazanjian A, Wallis D, Au N, et al: Growth factor independence-1 is expressed in primary human neuroendocrine lung carcinomas and mediates the differentiation of murine pulmonary neuroendocrine cells. Cancer Res 64: 3874-6882, 2004
7. Marchetti A, Martella C, Felicioni L, et al: EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 23: 857-865, 2005
8. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004
9. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004
10. Amann J, Kalyankrishna S, Massion PP, et al: Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res 65: 226-235, 2005
11. Cancer Genome Project and Collaborative Group. Nature 431: 525-526, 2004
12. West KA, Linnoila JR, Brognard J. et al: Tobacco carcinogen-induced cellular transformation increases Akt activation in vitro and in vivo. Chest 125: 101S-102S, 2004
13. De Benedetti A, Graff JR: eIF expression and its role in malignancies and metastases. Oncogene 23: 3189-3199, 2004
14. Sugita M, Geraci M, Gao B, et al: Combined use of oligonucleotide and tissue microarray identifies cancer/testis antigens as biomarkers in lung carcinoma. Cancer Res 62: 3971-3979, 2002
15. Belinsky SA: Gene-promoter hypermethylation as a biomarker in lung cancer. Nature Rev Cancer 4: 707-717, 2004
16. Mazieres J, He B, You L, et al: Wnt inhibitory factor-1 is silenced by promoter hypermethylation in lung cancer. Cancer Res 64: 4717-4720, 2004
17. Garber ME, Troyanskaya OG, Schluens K, et al: Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci USA 98: 13784-13789, 2001
18. Bhattacharjee A, Richards WG, Staunton J, et al: Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 98: 13790-13795, 2001
19. Wigle DA, Jurisica I, Radulovich N, et al: Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. Cancer Res 62: 3005-3008, 2002
20. Kaminski N, Krupsky M: Gene expression patterns, prognostic and diagnostic markers, and lung cancer biology. Chest 125: 111S-115S, 2004
21. Beer DG, Kardia SL, Huang CC, et al: Gene expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 8: 816-824, 2002
22. Gordon GJ, Jensen RV, Hsiao LL, et al: Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma. Cancer Res 62: 4963-4967, 2002
23. Martin B, Paesmans M, Mascaux C et al: Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer 91:2018-2025, 2004
24. Lu C, Soria J-C, Tang X, et al: Prognostic factors in resected stage I non-small-cell lung cancer, a multivariate analysis of six molecular markers. J Clin Oncol 22:4575-4583, 2004
25. Mehdi SA, Tatum AH, Newman NB et al: Prognostic markers in resected stage I and II non-small-cell lung cancer: an analysis of 260 patients with 5 year follow-up. Clin Lung Cancer 1:59-67, 1999
26. Masuya D, Huang C, Liu D, et al: The tumour-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients. Br J Cancer 90:1555-1562, 2004
27. Fukuoka J, Fujii T, Shih JH et al: Chromatin remodeling factors and BRM/BRG1 expression as prognostic indicators in non-small cell lung cancer. Clin Cancer Res 10:4314-4324, 2004
28. Goncharuk VN, del-Rosario A, Kren L et al: Co-downregulation of PTEN, KAI-1, and nm23-H1 tumor/metastasis suppressor proteins in non-small cell lung cancer. Ann Diagn Pathol 8:6-16, 2004
29. Diederichs S, Bulk E, Steffen B et al: S100 family members and trypsinogens are predictors of distant metastasis and survival in early-stage non-small cell lung cancer. Cancer Res 64:5564-5569, 2004
30. Simi L, Andreani M, Davini F et al: Simultaneous measurement of MMP9 and TIMP1 mRNA in human non small cell lung cancers by multiplex real time RT-PCR. Lung Cancer 45:171-179, 2004
31. Takahashi H, Ebihara S, Okazaki T et al: Clinical significance of heparanase activity in primary resected non-small cell lung cancer. Lung Cancer 45:207-214, 2004
32. Shah L, Walter KL, Borczuk AC et al: Expression of Syndecan-1 and expression of epidermal growth factor receptor are associated with survival in patients with nonsmall cell lung carcinoma. Cancer 101:1632-1638, 2004
33. O-charoenrat P, Rusch V, Talbot SG et al: Casein kinase II alpha subunit and C1-inhibitor are independent predictors of outcome in patients with squamous cell carcinoma of the lung. Clin Cancer Res 10:5709-5803, 2004
34. Au NHC, Cheang M, Huntsman DG et al: Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers. J Pathol 204:101-109, 2004
35. L, and Bax in locally advanced squamous cell carcinoma of he lung. Lung Cancer 45:181-188, 2004
36. Toledo G, Sola JJ, Lorenzo MD et al: Loss of FHIT protein expression is related to high proliferation, low apoptosis and worse prognosis in non-small-cell lung carcinoma. Mod Pathol 17:440-448, 2004
37. Aljada IS, Rammath N, Donohue K et al: Upregulation of the tissue inhibitor of metalloproteinase-1 protein is associated with progression of human non-small-cell lung cancer. J Clin Oncol 22:3218-3229, 2004
38. Tsutsumida H, Goto M, Kitajima S et al: Combined status of MUC1 mucin and surfactant apoprotein A expression can predict the outcome of patients with small-size lung adenocarcinoma. Histopathology 44: 147-155, 2004
39. Ramaswamy S, Ross KN, Lander ES, Golub H: A molecular signature of metastasis in primary solid tumors. Nat Genet 33:49-54, 2003
40. Araki K, Hashimoto K, Ardyanto TD, et al: Co-expression of Cox-2 and EGFR in stage I human bronchial adenocarcinomas. Lung Cancer 45:161-169, 2004
41. Yamaguchi NH, Lichtens AJ, Dmarchi LM et al: COX-2, MMP-9, and Noguchi classification provide additional prognostic information about adenocarcinoma of the lung. A study of 117 patients from Brazil. Am J Clin Pathol 121:78-86, 2004
42. Pelosi G, Barisella M, Pasini F et al: CD117 immunoreactivity in stage I adenocarcinoma and squamous cell carcinoma of the lung: relevance to prognosis in a subset of adenocarcinoma patients. Mod Pathol 17:711-721, 2004
43. Jones MH, Virtanen C, Honjoh D et al: Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles. Lancet 363:775-781, 2004
44. Rohr U-P, Rehfeld N, Pflugfelder L et al: Expression of the tyrosine kinase C-kit is an independent prognostic factor in patients with small cell lung cancer. Int J Cancer 111:159-263, 2004
45. He P, Varticovski L, Bowman ED, et al: Identification of carboxypeptidase E and γ-glutamyl hydrolase as biomarkers for pulmonary neuroendocrine tumors by cDNA microarray. Hum Pathol 35:1196-1209, 2004
46. Koukourakis Ml, Giatromanolaki A, Sivridis E et al: Lactate dehydrogenase-5 (LDH-5) overexpression in non-small cell lung cancer tissues is linked to tumour hypoxia, angiogenetic factor production and poor prognosis. Br J Cancer 89:877-885, 2003
47. Nakashima T, Huan C, Liu D et al: Expression of vascular endothelial growth factor-A and vascular endothelial growth factor-C as prognostic factors for non-small cell lung cancer. Med Sci Monit 10:BR157-165, 2004
48. Iwasaki A, Kuwahara M, Yoshinaga Y, Shirakusa T: Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC. Eur J Cardio-thoracic Surg 25:443-448, 2004
49. Ogawa E, Takenaka K, Yanagihara K et al: Clinical significance of VEGF-C status in tumor cells and stromal macrophages in non-small cell lung cancer patients. Br J Cancer 91:498-503, 2004
50. Mineto TC, Ambrogi V, Baldi A et al: Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung carcinoma. J Clin Pathol 57:591-597, 2004
51. Tanaka F, Yanagihara K, Otake Y et al: Prognostic factors in resected pathologic (p-) stage IIIA-N2, non-small-cell lung carcinoma. Ann Surg Oncol 11:612-618, 2004
52. Stefanou D, Batistatou A, Arkoumani E et al: Expression of vascular endothelial growth factor (VEGF) and association with microvessel density in small-cell and non-small cell lung carcinoma. Histol Histopathol 19:37-42, 2004